Scientist have found evidences of where the brain records the place and time of real-life memories. In a study published in Proceedings of the National Academy of Science, Ohio State University researchers showed that the brain patterns related to the activation of this specific region when memories were recalled were a clear…
The biggest risk factor for Alzheimer’s disease (AD) is aging. After the age of 65 the risk doubles every 5 years, with over 40% of those aged 85 and older expected to develop the debilitating condition. Scientists at the Washington University School of Medicine in St. Louis managed to identify some of the crucial changes that occur in the brain…
A scientist from the University of Oklahoma is developing a new therapy to address Alzheimer’s disease using “biopharmaceutical proteases” to destroy the toxic plaque that piles up in the brain of Alzheimer’s patients. This approach will have significantly lower costs in the treatment of the disease while at the same time it has the potential to…
The Alzheimer’s Association and the Paul G. Allen Family Foundation recently announced the award of three grants to assess the role of the immune system in Alzheimer’s disease. The awards represent an investment of $500,000 to advance this understudied yet immense area of scientific knowledge, which could play a major role…
The summer solstice is the longest day of the year, and it is not just for baseball games and backyard barbecues. Every year on the summer solstice, the Alzheimer’s Association hosts “The Longest Day,” which is a team event to raise awareness and funds for Alzheimer’s. This year, teams from all…
A new drug developed at Lancaster University in the United Kingdom that might help to prevent early stages of Alzheimer’s disease and is about to enter clinical trials. The number of individuals affected by dementia is constantly increasing. According to estimates, there are 850,000 cases in the United Kingdom currently, with estimates that the number…
Aphios Corporation recently announced that United States Patent 9,034,347 has been granted to the company’s lead compound to treat neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, Hutchinson Disease and Down’s syndrome. Alzheimer’s disease, Parkinson’s disease, Hutchinson’s Disease, Kuru Creutzfeldt-Jakob disease, further spongiform encephalopathies and all neurodegenerative diseases in general remain enormous health problems with numerous…
The existence of specific and reliable biomarkers for Alzheimer’s disease are crucial to identifying individuals to enroll in clinical trials so that drugs can be tested and diseases can be detected as soon as possible. Facilitating clinical trial enrollment allows studies that are researching and developing therapies that stop or slow Alzheimer’s disease progression…
NuevaCare recently announced that it will be presenting MnemeTherapy®, its service to address Alzheimer’s disease, at two upcoming seminars. The first will be held on Wednesday, May 6 at the PSA Annual Regional Stroke Conference at The Magnolia of Millbrae; the second will take place on Wednesday, May 13 at the Dementia…
CereSpir™ Incorporated, a biotechnology company firm advancing CSP-1103, which is a first-in-class modulator of the innate immune system of the brain to address treatment for Alzheimer’s disease, recently announced that Sophie Egholm has been appointed as Chief Operating Officer of the company. Egholm is a pharmacologist and medicinal chemist who has spent her…
Get regular updates to your inbox.